-
公开(公告)号：US12029746B2
公开(公告)日：2024-07-09
申请号：US17254674
申请日：2019-06-20
申请人： KAO CORPORATION
发明人： Yusuke Kobayashi , Yuichi Shimoda , Hiroko Uchida , Sho Aida , Shun Sakoda
IPC分类号： A61K31/7048 , A23L27/00 , A23L27/10 , A23L27/30 , A23L33/00 , A61K9/16 , A61K9/20 , A61K9/68 , A61K31/11 , A61K31/352
CPC分类号： A61K31/7048 , A23L27/10 , A23L27/33 , A23L27/88 , A23L33/30 , A61K9/0058 , A61K9/16 , A61K9/20 , A61K31/11 , A61K31/352
摘要： Provided is an oral composition, including the following components (A), (B), and (C): (A) non-polymer catechins; (B) rutin; and (C) astragalin, wherein a content of the component (A) in solids is from 2 mass % to 50 mass %, wherein a mass ratio between the component (A) and the component (B), [(B)/(A)], is from 0.05×10−2 to 50×10−2, and wherein a mass ratio between the component (A) and the component (C), [(C)/(A)], is from 1.0×10−3 to 50×10−3.
-
公开(公告)号：US11911375B2
公开(公告)日：2024-02-27
申请号：US17098550
申请日：2020-11-16
申请人： Fertin Pharma A/S
发明人： Kent Albin Nielsen , Jessie Poulsen
IPC分类号： A61K31/465 , A61K9/68 , A61K9/20 , A61K47/02 , A61K47/14 , A61K47/26 , A61K47/32 , A61K47/44
CPC分类号： A61K31/465 , A61K9/0058 , A61K9/2009 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2068 , A61K47/02 , A61K47/14 , A61K47/26 , A61K47/32 , A61K47/44
摘要： A solid oral nicotine formulation is disclosed, the formulation comprises a nicotine-ion exchange resin combination, and a salt comprising inorganic divalent cations, wherein the salt has a water-solubility of at least 5 grams per 100 mL of water measured at 25 degrees Celsius, atmospheric pressure and pH 7.0.
-
公开(公告)号：US11883388B2
公开(公告)日：2024-01-30
申请号：US16897849
申请日：2020-06-10
IPC分类号： A61K31/445 , A61P11/00 , A61K31/192 , A61K31/4545 , A61K31/616 , A61K31/4535 , A61K9/00 , A61K9/68 , A61K9/20
CPC分类号： A61K31/445 , A61K9/0056 , A61K9/0058 , A61K9/2004 , A61K31/192 , A61K31/4535 , A61K31/4545 , A61K31/616 , A61P11/00
摘要： The present invention relates to a method of reducing or preventing the symptoms associated with the common cold. The method comprises administering to a subject an effective amount of a pharmaceutical composition before presenting with at least one symptom of the common cold. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, salts thereof, and combinations thereof.
-
公开(公告)号：US20230404867A1
公开(公告)日：2023-12-21
申请号：US18149989
申请日：2023-01-04
IPC分类号： A61K8/19 , A61K8/24 , A61Q11/00 , A61K33/42 , A61K33/24 , A61K9/00 , A61K9/68 , A61K6/20 , A61K6/74
CPC分类号： A61K8/19 , A61K8/24 , A61Q11/00 , A61K33/42 , A61K33/24 , A61K9/0056 , A61K9/006 , A61K9/0058 , A61K6/20 , A61K6/74 , A61K2800/52
摘要： The present invention relates to improved complexes of amorphous calcium phosphate and/or amorphous calcium fluoride phosphate stabilised by phosphopeptides/phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental/medical applications (including anti-calculus, anti-erosion/corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion/corrosion and dental hypersensitivity are also provided.
-
公开(公告)号：US20230346824A1
公开(公告)日：2023-11-02
申请号：US17918679
申请日：2021-04-14
申请人： SolyPlus GmbH , Leopold GmbH
IPC分类号： A23L29/275 , A23G4/10 , A23L2/52 , A61K31/722 , A61K31/7004 , A61K31/522 , A61K9/68 , A61P31/14
CPC分类号： A61K31/722 , A23G4/10 , A23L2/52 , A23L29/275 , A61K9/0058 , A61K31/522 , A61K31/7004 , A61P31/14
摘要： A composition for use in preventing an infection, or treating an infection, or treating a disease caused by an infection, the composition including a compound selected from the group of chitosan or a salt thereof, galactose, mannose, caffeine, and any combination thereof.
-
公开(公告)号：US11717537B2
公开(公告)日：2023-08-08
申请号：US17832556
申请日：2022-06-03
CPC分类号： A61K33/42 , A61K8/21 , A61K8/24 , A61K8/64 , A61K9/0058 , A61K47/42 , A61Q11/00 , A61K2800/28 , A61K2800/592
摘要： The present invention relates to compositions for mineralizing a dental surface, in particular tooth enamel. Methods of mineralizing hypomineralized lesions (including subsurface lesions) in the tooth enamel caused by dental caries, dental corrosion and fluorosis are also provided. In particular, the invention relates to a method of mineralizing a dental surface or subsurface comprising contacting the dental surface or subsurface with a compound that is capable of increasing or maintaining the pH of a solution and a mineralizing agent.
-
公开(公告)号：US11717536B2
公开(公告)日：2023-08-08
申请号：US16492900
申请日：2018-03-14
CPC分类号： A61K33/42 , A61K9/0058 , A61K38/1709
摘要： The present invention relates to compositions and their use for oral care. In particular, the compositions and methods are for maintaining oral health and/or treating various oral conditions such as gingivitis. The present invention relates to methods and uses of stabilized amorphous calcium phosphate (ACP) and/or stabilized amorphous calcium fluoride phosphate (ACFP) in the preparation of a medicament for reducing pathogenic oral bacteria at an oral site in an individual; increasing commensal oral bacteria at an oral site in an individual; decreasing the proportion of pathogenic oral bacteria at an oral site in an individual; inhibiting oral dysbiosis; reducing gingival inflammation in an individual in need thereof; treating gingivitis in an individual in need thereof; and treating chronic gingivitis in an individual in need thereof.
-
公开(公告)号：US20230241186A1
公开(公告)日：2023-08-03
申请号：US16301000
申请日：2018-05-14
IPC分类号： A61K38/47 , A61K31/045 , A61K31/352 , A61K31/05 , A61K31/618 , A61K9/68 , A61P31/04
CPC分类号： A61K38/47 , A61K31/045 , A61K31/352 , A61K31/05 , A61K31/618 , A61K9/0058 , A61P31/04
摘要： The invention provides a method for combating biofilm, said method comprising contacting a biofilm with a composition comprising effective amounts of one or more biofilm degrading enzymes in combination with antimicrobial agents or antimicrobial essential oils. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In a preferred aspect the invention provides a composition and method for use in the treatment or prevention of a biofilm infection in a subject, particularly in the oral cavity.
-
公开(公告)号：US20230241165A1
公开(公告)日：2023-08-03
申请号：US17923907
申请日：2021-05-07
申请人： ESS HOLDING GmbH
发明人： Alireza ESLAMIAN , Martin SCHIFKO
CPC分类号： A61K38/1732 , A61K38/168 , A61K9/0014 , A61P31/14 , A61K9/006 , A61K9/0058 , A61K9/0056 , A61K9/0043 , A61K9/0048
摘要： The present invention is, inter alia, directed towards mannose-binding lectin and compositions comprising mannose-binding lectin for use in treatment or prophylaxis, towards compositions comprising mannose-binding lectin and towards the use of mannose-binding lectin and said compositions. Mannose-binding lectin, or portions thereof are applied locally according to the invention. MBL is binding to a pathogen to prevent it from binding to a host cell by blocking the binding sites of the pathogen. As a result, infection or transmission of disease can be avoided.
-
公开(公告)号：US20230190729A1
公开(公告)日：2023-06-22
申请号：US18108135
申请日：2023-02-10
申请人： Sesh Products Inc.
CPC分类号： A61K31/465 , A61K9/009 , A61K9/0058 , A24B15/16 , A23G3/48 , A61K9/146 , A61K9/006
摘要： A nicotine oral delivery product contains a powder enclosed in a water insoluble pouch, wherein the pouch is permeable for saliva and therein dissolved parts of the powder, wherein the powder comprises at least (a) nicotine selected from the group consisting of tobacco, nicotine salts, nicotine base, stabilized nicotine, and mixtures thereof corresponding to 0.1 to 20 mg nicotine in the form of nicotine base and (b) a chewing gum composition. A method is provided for producing the nicotine oral delivery product.
-
-
-
-
-
-
-
-
-
搜索结果
1348 条记录 (耗时 0.029 秒)
